Miriqules will demonstrate blood delivery technology at Techchuncing disrupt 2025

MiraQules co-founder and CEO Tribe Mossain Always knew he wanted to follow in his father’s footsteps and run his own business. But he never thought that he would change the biotech company built around the technology that would be able to help his father after a tragic accident that was close to death.

Khalaqules base that Bengalangu developed. Blood curd powder quickly produces a fibrous compound at a higher room temperature for comparison and can absorb blood quickly when applied.

“This is a product that will give you your feedback immediately,” Hossain told Techkuncid. “If someone feels, you apply it, and the bleeding stops. This thing happens in a minute or two.”

Gairaqules is the end of 20 State Fast Design and will present this technology on stage on stage at Techkuncure 2025, this week in San Francisco.

Hentsive says he developed the technology almost by accident.

He went to school to study biochemistry and started working at a laboratory in the field of biology where his duties were basic.

“I’m really bad at it, actually,” Hossain said. “The purpose is to create a 3D structure that will help in tissue growth, which can help in bone generation. Every time I am inspired.” It gets disnothized.

One day he took the guiding particles and ground them into powder. He lived this flower to the gujang who worked on his dete that struggled to mix the correct solution to see if it could help – it could help – it worked.

“It followed all the blood in the possibility of five to 10 seconds. I rushed to my professor and then from Mardio I also started to think,” Hoseny. “We came up with a new process that combines off-the-shelf materials into nanomaterials that mimic blood proteins.”

Hostra then got in touch with his childhood friend, middle age, and they started trying to develop the technology so that they could get labor – and as much labor as possible – and as much funding as possible.

Since then, the company has obtained 11 patents across different countries, including India, the United States, and Israel.

Tech MiraQules’ has already been piloted in a treatment center in Toraum in India, and the company hopes to improve its regulation in India. It is also on track to receive clearance from the US food and drug administration in 2026.

“One thing we did from the beginning, we directly went to the US FDA, there is something called pre-submission. We tried to get their feedback on what other necessary things that we need to do to get this product approved, that helped us a lot.”

The company has reached this milestone with more than $700,000 in capital invested, especially from the old.

Mirisqules was returned to rob the deployment and pilot program and next year. Tumatna has acquired the potential of 10 different hospital chains in India with Anhieli’s Output Defense Partner.

If you want to learn from Miriraqules Head here to learn more about this disturbing yearheld October 27 to 29 in San Francisco.